Dupixent and Mycosis Fungoides Lawsuit Review
This page is for patients and families who used Dupixent and were later diagnosed with mycosis fungoides or another CTCL / T-cell lymphoma diagnosis. The goal is to explain, in plain English, why diagnosis history and timing are being discussed in Dupixent litigation and what information may help when requesting an initial legal review.
Many people first hear unfamiliar terms like CTCL and mycosis fungoides after years of skin symptoms. This resource is designed to make that information easier to understand while keeping legal framing careful and accurate.
What is mycosis fungoides?
Mycosis fungoides is the most common form of cutaneous T-cell lymphoma (CTCL). It is a lymphoma that primarily affects the skin and can develop slowly over time.
In many histories, symptoms evolve over months or years, which can make timeline details especially important when a legal and medical review is requested.
Why can mycosis fungoides be confused with eczema or dermatitis?
Some symptoms may overlap with common inflammatory skin conditions. People may report persistent rash, patches, plaques, itching, or other skin changes that can appear similar to eczema or dermatitis.
Diagnosis may require biopsy, repeat evaluation, dermatology and pathology review, or oncology input, especially when symptoms change over time.
Why is mycosis fungoides relevant to Dupixent lawsuits?
Dupixent lawsuits are reviewing patient histories where Dupixent use was followed by CTCL-related diagnoses, including mycosis fungoides in some allegations.
Lawsuits allege that certain Dupixent treatment histories should have included stronger warnings or earlier recognition of CTCL-related concerns. These are litigation allegations, and case review may depend on diagnosis history, timing, and medical records.
No court has made a final determination on the allegations involving Dupixent, mycosis fungoides, or CTCL.
For broader background, read Dupixent and mycosis fungoides, Dupixent Lawsuit Overview, and Dupixent CTCL lawsuit updates.
What information may matter in an initial review?
- Whether Dupixent was used and when treatment began
- Why Dupixent was prescribed
- When skin symptoms began, changed, worsened, or failed to respond
- Whether mycosis fungoides, CTCL, Sézary syndrome, PTCL, or another T-cell lymphoma was diagnosed
- Diagnosis date
- Biopsy, pathology, dermatology, oncology records
- Whether another attorney already represents the matter
- State where treatment or diagnosis occurred
Related Dupixent CTCL resources
You may also want to review Dupixent, eczema, and CTCL diagnosis history, Dupixent and Sézary syndrome, Dupixent T-cell lymphoma case review records, and the initial review form.
What records should patients keep?
If available, these records can help create a clearer treatment and diagnosis timeline for an initial review:
- Biopsy/pathology reports
- Dermatology visit history
- Oncology notes
- Prescription/pharmacy history
- Dupixent prescription history
- Photos of skin progression, if available
- Diagnosis records
- Treatment timeline
Sources reviewed
- JPML and court materials
- Dupixent prescribing information
- FDA and safety materials
- Peer-reviewed medical literature regarding Dupixent, CTCL, and mycosis fungoides
Last reviewed: May 22, 2026
You do not need to have every record before asking for an initial review. Basic information about diagnosis, timing, treatment history, and state may help determine whether follow-up is appropriate.
Start Free Case Review
If you used Dupixent and were later diagnosed with mycosis fungoides, CTCL, or another T-cell lymphoma, you can submit basic information for an initial review.